Amenorrhea and Estrogen Disorders in Women with Kidney Disease

  • Kavitha VellankiEmail author
  • Holly Kramer


Endocrine abnormalities from altered synthesis and metabolism of sex hormones are a common feature in both men and women with chronic kidney disease (CKD). Despite the fact that kidney disease affects approximately one out of ten women in the United States and one out of five women over the age of 60 years, women’s health issues in the setting of CKD remain one of the most neglected and under-recognized issues in clinical practice. While the exact mechanisms are unclear, impairment in the hypothalamic-pituitary axis due to uremia, underlying comorbid conditions, and concomitant medication use are thought to play a predominant role. Abnormal menstrual cycles with amenorrhea, often associated with anovulation, are common in premenopausal women with kidney disease. Early menopause is also common in CKD with the potential negative effects of early menopause on cardiovascular and bone health poorly determined. Diagnosis and management of menopausal symptoms and postmenopausal osteoporosis in CKD remain challenging and controversial. Sexual dysfunction is highly prevalent in women on dialysis, but these symptoms improve markedly post-kidney transplant. While infertility is common, restoration of fertility in women with moderate to severe non-dialysis-dependent CKD should be discouraged due to risk of CKD progression.


Women’s health Menstrual disorders Amenorrhea Kidney disease Kidney failure End-stage renal disease Contraception Menopause Hot flashes Estrogen 


  1. 1.
    U S Renal Data System. USRDS 2013 annual data report: Atlas of chronic kidney disease and end-stage renal disease in the United States. Bethesda: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney DiseasesGoogle Scholar
  2. 2.
    Anantharaman P, Schmidt RJ. Sexual function in chronic kidney disease. Adv Chronic Kidney Dis. 2007;14(2):119–25.PubMedGoogle Scholar
  3. 3.
    Holley JL, Schmidt RJ, Bender FH, Dumler F, Schiff M. Gynecologic and reproductive issues in women on dialysis. Am J Kidney Dis. 1997;29(5):685–90.PubMedGoogle Scholar
  4. 4.
    Lim VS. Reproductive function in patients with renal insufficiency. Am J Kidney Dis. 1987;9(4):363–7.PubMedGoogle Scholar
  5. 5.
    Matuszkiewicz-Rowinska J, Skorzewska K, Radowicki S, Niemczyk S, Sokalski A, Przedlacki J, Puka J, Switalski M, Wardyn K, Grochowski J, et al. Endometrial morphology and pituitary-gonadal axis dysfunction in women of reproductive age undergoing chronic haemodialysis – a multicentre study. Nephrol Dial Transplant. 2004;19(8):2074–7.PubMedGoogle Scholar
  6. 6.
    Morley JE, Distiller LA, Epstein S, Katz M, Gold C, Sagel J, Kaye G, Pokroy M, Kalk J. Menstrual disturbances in chronic renal failure. Horm Metab Res. 1979;11(1):68–72.PubMedGoogle Scholar
  7. 7.
    Holley JL. The hypothalamic-pituitary axis in men and women with chronic kidney disease. Adv Chronic Kidney Dis. 2004;11(4):337–41.PubMedGoogle Scholar
  8. 8.
    Lim VS, Henriquez C, Sievertsen G, Frohman LA. Ovarian function in chronic renal failure: evidence suggesting hypothalamic anovulation. Ann Intern Med. 1980;93(1):21–7.PubMedGoogle Scholar
  9. 9.
    Ginsburg ES, Owen WF. Reproductive endocrinology and pregnancy in women on hemodialysis. Semin Dial. 1993;6:105–16.Google Scholar
  10. 10.
    Lim VS, Kathpalia SC, Frohman LA. Hyperprolactinemia and impaired pituitary response to suppression and stimulation in chronic renal failure: reversal after transplantation. J Clin Endocrinol Metab. 1979;48(1):101–7.PubMedGoogle Scholar
  11. 11.
    Holley JL, Schmidt RJ. Changes in fertility and hormone replacement therapy in kidney disease. Adv Chronic Kidney Dis. 2013;20(3):240–5.Google Scholar
  12. 12.
    Sievertsen GD, Lim VS, Nakawatase C, Frohman LA. Metabolic clearance and secretion rates of human prolactin in normal subjects and in patients with chronic renal failure. J Clin Endocrinol Metab. 1980;50(5):846–52.PubMedGoogle Scholar
  13. 13.
    Vance ML, Evans WS, Thorner MO. Drugs five years later. Bromocriptine. Ann Intern Med. 1984;100(1):78–91.PubMedGoogle Scholar
  14. 14.
    Wolf G, Chen S, Han DC, Ziyadeh FN. Leptin and renal disease. Am J Kidney Dis. 2002;39(1):1–11.PubMedGoogle Scholar
  15. 15.
    Singh AK, Raed A, Kari J. Endocrine complications of chronic kidney disease. In: Kimmel PL, Rosenberg ME, editors. Chronic kidney diseases. 1st ed. New York: Academic; 2014. p. 310–9.Google Scholar
  16. 16.
    Matuszkiewicz-Rowinska J, Skorzewska K, Radowicki S, Sokalski A, Przedlacki J, Niemczyk S, Wlodarczyk D, Puka J, Switalski M. The benefits of hormone replacement therapy in pre-menopausal women with oestrogen deficiency on haemodialysis. Nephrol Dial Transplant. 1999;14(5):1238–43.PubMedGoogle Scholar
  17. 17.
    Filocamo MT, Zanazzi M, Li Marzi V, Lombardi G, Del Popolo G, Mancini G, Salvadori M, Nicita G. Sexual dysfunction in women during dialysis and after renal transplantation. J Sex Med. 2009;6(11):3125–31.PubMedGoogle Scholar
  18. 18.
    Ghazizadeh S, Lessan-Pezeshki M, Mahdavi M, Razeghi E, Seifi S. Menstrual problems among kidney transplant recipients. Transplant Proc. 2003;35(7):2720–1.PubMedGoogle Scholar
  19. 19.
    Noohi S, Azar M, Behzadi AH, Barbati ME, Haghshenas A, Amoozgar B, Karami M. Comparison of sexual function in females receiving haemodialysis and after renal transplantation. J Ren Care. 2010;36(4):212–7.PubMedGoogle Scholar
  20. 20.
    Pertuz W, Castaneda DA, Rincon O, Lozano E. Sexual dysfunction in patients with chronic renal disease: does it improve with renal transplantation? Transplant Proc. 2014;46(9):3021–6.PubMedGoogle Scholar
  21. 21.
    Wang GC, Zheng JH, Xu LG, Min ZL, Zhu YH, Qi J, Duan QL. Measurements of serum pituitary-gonadal hormones and investigation of sexual and reproductive functions in kidney transplant recipients. Int J Nephrol. 2010;2010:612126.PubMedPubMedCentralGoogle Scholar
  22. 22.
    Kim JH, Chun CJ, Kang CM, Kwak JY. Kidney transplantation and menstrual changes. Transplant Proc. 1998;30(7):3057–9.PubMedGoogle Scholar
  23. 23.
    Taylor AE, Adams JM, Mulder JE, Martin KA, Sluss PM, Crowley WF Jr. A randomized, controlled trial of estradiol replacement therapy in women with hypergonadotropic amenorrhea. J Clin Endocrinol Metab. 1996;81(10):3615–21.PubMedGoogle Scholar
  24. 24.
    Koyama H, Wada T, Nishizawa Y, Iwanaga T, Aoki Y. Cyclophosphamide-induced ovarian failure and its therapeutic significance in patients with breast cancer. Cancer. 1977;39(4):1403–9.PubMedGoogle Scholar
  25. 25.
    Houssiau FA, Vasconcelos C, D'Cruz D, Sebastiani GD, Garrido Ed Ede R, Danieli MG, Abramovicz D, Blockmans D, Mathieu A, Direskeneli H, et al. Immunosuppressive therapy in lupus nephritis: the euro-lupus nephritis trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum. 2002;46(8):2121–31.PubMedGoogle Scholar
  26. 26.
    Jayne D, Rasmussen N, Andrassy K, Bacon P, Tervaert JW, Dadoniene J, Ekstrand A, Gaskin G, Gregorini G, de Groot K, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med. 2003;349(1):36–44.PubMedGoogle Scholar
  27. 27.
    Rauen T, Eitner F, Fitzner C, Sommerer C, Zeier M, Otte B, Panzer U, Peters H, Benck U, Mertens PR, et al. Intensive supportive care plus immunosuppression in IgA nephropathy. N Engl J Med. 2015;373(23):2225–36.PubMedGoogle Scholar
  28. 28.
    Clowse ME, Behera MA, Anders CK, Copland S, Coffman CJ, Leppert PC, Bastian LA. Ovarian preservation by GnRH agonists during chemotherapy: a meta-analysis. J Womens Health (Larchmt). 2009;18(3):311–9.Google Scholar
  29. 29.
    Munhoz RR, Pereira AA, Sasse AD, Hoff PM, Traina TA, Hudis CA, Marques RJ. Gonadotropin-releasing hormone agonists for ovarian function preservation in premenopausal women undergoing chemotherapy for early-stage breast cancer: a systematic review and meta-analysis. JAMA Oncol. 2016;2(1):65–73.PubMedPubMedCentralGoogle Scholar
  30. 30.
    Somers EC, Marder W, Christman GM, Ognenovski V, McCune WJ. Use of a gonadotropin-releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus. Arthritis Rheum. 2005;52(9):2761–7.PubMedGoogle Scholar
  31. 31.
    Hou S. Daily dialysis in pregnancy. Hemodial Int. 2004;8(2):167–71.PubMedGoogle Scholar
  32. 32.
    Souqiyyeh MZ, Huraib SO, Saleh AG, Aswad S. Pregnancy in chronic hemodialysis patients in the Kingdom of Saudi Arabia. Am J Kidney Dis. 1992;19(3):235–8.PubMedGoogle Scholar
  33. 33.
    Toma H, Tanabe K, Tokumoto T, Kobayashi C, Yagisawa T. Pregnancy in women receiving renal dialysis or transplantation in Japan: a nationwide survey. Nephrol Dial Transplant. 1999;14(6):1511–6.PubMedGoogle Scholar
  34. 34.
    Barua M, Hladunewich M, Keunen J, Pierratos A, McFarlane P, Sood M, Chan CT. Successful pregnancies on nocturnal home hemodialysis. Clin J Am Soc Nephrol. 2008;3(2):392–6.PubMedPubMedCentralGoogle Scholar
  35. 35.
    Imbasciati E, Gregorini G, Cabiddu G, Gammaro L, Ambroso G, Del Giudice A, Ravani P. Pregnancy in CKD stages 3 to 5: fetal and maternal outcomes. Am J Kidney Dis. 2007;49(6):753–62.PubMedGoogle Scholar
  36. 36.
    Jones DC, Hayslett JP. Outcome of pregnancy in women with moderate or severe renal insufficiency. N Engl J Med. 1996;335(4):226–32.PubMedGoogle Scholar
  37. 37.
    Okundaye I, Abrinko P, Hou S. Registry of pregnancy in dialysis patients. Am J Kidney Dis. 1998;31(5):766–73.PubMedGoogle Scholar
  38. 38.
    Ahmed SB, Hovind P, Parving HH, Rossing P, Price DA, Laffel LM, Lansang MC, Stevanovic R, Fisher ND, Hollenberg NK. Oral contraceptives, angiotensin-dependent renal vasoconstriction, and risk of diabetic nephropathy. Diabetes Care. 2005;28(8):1988–94.PubMedGoogle Scholar
  39. 39.
    Baillargeon JP, McClish DK, Essah PA, Nestler JE. Association between the current use of low-dose oral contraceptives and cardiovascular arterial disease: a meta-analysis. J Clin Endocrinol Metab. 2005;90(7):3863–70.PubMedGoogle Scholar
  40. 40.
    Fung MM, Poddar S, Bettencourt R, Jassal SK, Barrett-Connor E. A cross-sectional and 10-year prospective study of postmenopausal estrogen therapy and blood pressure, renal function, and albuminuria: the Rancho Bernardo Study. Menopause. 2011;18(6):629–37.PubMedPubMedCentralGoogle Scholar
  41. 41.
    Monster TB, Janssen WM, de Jong PE, de Jong-van den Berg LT, Prevention of Renal and Vascular End Stage Disease Study Group. Oral contraceptive use and hormone replacement therapy are associated with microalbuminuria. Arch Intern Med. 2001;161(16):2000–5.PubMedGoogle Scholar
  42. 42.
    Krajewski CM, Geetha D, Gomez-Lobo V. Contraceptive options for women with a history of solid-organ transplantation. Transplantation. 2013;95(10):1183–6.PubMedGoogle Scholar
  43. 43.
    Ramhendar T, Byrne P. Use of the levonorgestrel-releasing intrauterine system in renal transplant recipients: a retrospective case review. Contraception. 2012;86(3):288–9.PubMedGoogle Scholar
  44. 44.
    Kramer HM, Curhan GC, Singh A, Hemodialysis and Estrogen Levels in Postmenopausal Patients Study Group. Permanent cessation of menses and postmenopausal hormone use in dialysis-dependent women: the HELP study. Am J Kidney Dis. 2003;41(3):643–50.PubMedGoogle Scholar
  45. 45.
    Cheung KL, Stefanick ML, Allison MA, LeBlanc ES, Vitolins MZ, Shara N, Chertow GM, Winkelmayer WC, Kurella Tamura M. Menopausal symptoms in women with chronic kidney disease. Menopause. 2015;22(9):1006–11.PubMedPubMedCentralGoogle Scholar
  46. 46.
    Kramer HM, Curhan G, Singh A, HELP Study Group. Hemodialysis and estrogen levels in postmenopausal (HELP) patients: the multicenter HELP study. Am J Kidney Dis. 2003;41(6):1240–6.PubMedGoogle Scholar
  47. 47.
    Greendale GA, Sowers M, Han W, Huang MH, Finkelstein JS, Crandall CJ, Lee JS, Karlamangla AS. Bone mineral density loss in relation to the final menstrual period in a multiethnic cohort: results from the study of women’s health across the nation (SWAN). J Bone Miner Res. 2012;27(1):111–8.PubMedPubMedCentralGoogle Scholar
  48. 48.
    Slemenda C, Longcope C, Peacock M, Hui S, Johnston CC. Sex steroids, bone mass, and bone loss. A prospective study of pre-, peri-, and postmenopausal women. J Clin Invest. 1996;97(1):14–21.PubMedPubMedCentralGoogle Scholar
  49. 49.
    Sowers M, Crutchfield M, Bandekar R, Randolph JF, Shapiro B, Schork MA, Jannausch M. Bone mineral density and its change in pre-and perimenopausal white women: the Michigan Bone Health Study. J Bone Miner Res. 1998;13(7):1134–40.PubMedGoogle Scholar
  50. 50.
    Moe S, Drueke T, Cunningham J, Goodman W, Martin K, Olgaard K, Ott S, Sprague S, Lameire N, Eknoyan G, et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2006;69(11):1945–53.PubMedGoogle Scholar
  51. 51.
    Cummings SR, Bates D, Black DM. Clinical use of bone densitometry: scientific review. JAMA. 2002;288(15):1889–97.PubMedGoogle Scholar
  52. 52.
    Sherman ME, Shepherd J, Frassetto L, Genant HK. Discrepancy in results between spine and hip scans of a woman with end stage renal disease. J Clin Densitom. 2002;5(1):95–8.PubMedGoogle Scholar
  53. 53.
    Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int. 2009;113:S1–S130.Google Scholar
  54. 54.
    Jamal SA, Bauer DC, Ensrud KE, Cauley JA, Hochberg M, Ishani A, Cummings SR. Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial. J Bone Miner Res. 2007;22(4):503–8.PubMedGoogle Scholar
  55. 55.
    Miller PD, Roux C, Boonen S, Barton IP, Dunlap LE, Burgio DE. Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials. J Bone Miner Res. 2005;20(12):2105–15.PubMedGoogle Scholar
  56. 56.
    Ishani A, Blackwell T, Jamal SA, Cummings SR, Ensrud KE, MORE Investigators. The effect of raloxifene treatment in postmenopausal women with CKD. J Am Soc Nephrol. 2008;19(7):1430–8.PubMedPubMedCentralGoogle Scholar
  57. 57.
    Hernandez E, Valera R, Alonzo E, Bajares-Lilue M, Carlini R, Capriles F, Martinis R, Bellorin-Font E, Weisinger JR. Effects of raloxifene on bone metabolism and serum lipids in postmenopausal women on chronic hemodialysis. Kidney Int. 2003;63(6):2269–74.PubMedGoogle Scholar
  58. 58.
    Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women's health initiative randomized controlled trial. JAMA. 2002;288(3):321–33.PubMedGoogle Scholar
  59. 59.
    Grady D, Applegate W, Bush T, Furberg C, Riggs B, Hulley SB. Heart and estrogen/progestin replacement study (HERS): design, methods, and baseline characteristics. Control Clin Trials. 1998;19(4):314–35.PubMedGoogle Scholar
  60. 60.
    Shlipak MG, Simon JA, Grady D, Lin F, Wenger NK, Furberg CD, Heart and Estrogen/Progestin Replacement Study (HERS) Investigators. Renal insufficiency and cardiovascular events in postmenopausal women with coronary heart disease. J Am Coll Cardiol. 2001;38(3):705–11.PubMedGoogle Scholar
  61. 61.
    Ginsburg ES, Walsh B, Greenberg L, Price D, Chertow GM, Owen WF Jr. Effects of estrogen replacement therapy on the lipoprotein profile in postmenopausal women with ESRD. Kidney Int. 1998;54(4):1344–50.PubMedGoogle Scholar
  62. 62.
    North American Menopause Society. The 2012 hormone therapy position statement of: the North American Menopause Society. Menopause. 2012;19(3):257–71.Google Scholar
  63. 63.
    Stuenkel CA, Davis SR, Gompel A, Lumsden MA, Murad MH, Pinkerton JV, Santen RJ. Treatment of symptoms of the menopause: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2015;100(11):3975–4011.PubMedGoogle Scholar
  64. 64.
    Grady D. Clinical practice. Management of menopausal symptoms. N Engl J Med. 2006;355(22):2338–47.PubMedGoogle Scholar
  65. 65.
    Navaneethan SD, Vecchio M, Johnson DW, Saglimbene V, Graziano G, Pellegrini F, Lucisano G, Craig JC, Ruospo M, Gentile G, et al. Prevalence and correlates of self-reported sexual dysfunction in CKD: a meta-analysis of observational studies. Am J Kidney Dis. 2010;56(4):670–85.PubMedGoogle Scholar
  66. 66.
    Strippoli GF, Collaborative Depression and Sexual Dysfunction (CDS) in Hemodialysis Working Group, Vecchio M, Palmer S, De Berardis G, Craig J, Lucisano G, Johnson D, Pellegrini F, Nicolucci A, et al. Sexual dysfunction in women with ESRD requiring hemodialysis. Clin J Am Soc Nephrol. 2012;7(6):974–81.Google Scholar
  67. 67.
    Seethala S, Hess R, Bossola M, Unruh ML, Weisbord SD. Sexual function in women receiving maintenance dialysis. Hemodial Int. 2010;14(1):55–60.PubMedGoogle Scholar
  68. 68.
    Diemont WL, Vruggink PA, Meuleman EJ, Doesburg WH, Lemmens WA, Berden JH. Sexual dysfunction after renal replacement therapy. Am J Kidney Dis. 2000;35(5):845–51.PubMedGoogle Scholar
  69. 69.
    Ginsburg ES, Owen WF, Jr GLM, Shea BF, Lazarus JM, Walsh BW. Estrogen absorption and metabolism in postmenopausal women with end-stage renal disease. J Clin Endocrinol Metab. 1996;81(12):4414–7.PubMedGoogle Scholar
  70. 70.
    Anderson GD, Odegard PS. Pharmacokinetics of estrogen and progesterone in chronic kidney disease. Adv Chronic Kidney Dis. 2004;11(4):357–60.PubMedGoogle Scholar
  71. 71.
    Holley JL, Reddy SS. Pregnancy and CKD: lessons on communication from patients. Am J Kidney Dis. 2015;66(6):936–8.PubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Department of MedicineLoyola University Medical CenterMaywoodUSA
  2. 2.Department of Public Health Sciences and MedicineLoyola University Medical CenterMaywoodUSA

Personalised recommendations